| A Study to Evaluate TNX-102 SL Monotherapy Versus Placebo in Participants With Major Depressive Disorder (MDD) (NCT07621237) | Tonix Pharmaceuticals, Inc. | 2026-06-01 |
| A Phase 1, Open-Label, Parallel-Group, Single-Dose Study To Compare The Pharmakokinetics Of TNX-102 SL (Cyclobenzaprine Hydrochloride Sublingual Tablet) In Non-Elderly Versus Elderly Participants (NCT07413367) | Tonix Pharmaceuticals, Inc. | 2025-12-09 |
| Comparing Efficacy & Safety Of TNX-1300 To Placebo With UC For Treatment Of Acute Cocaine Intoxication In ED Subjects (CATALYST) (NCT06045793) | Tonix Pharmaceuticals, Inc. | 2024-08-16 |
| A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects (NCT07473752) | Tonix Pharmaceuticals, Inc. | 2023-07-18 |
| Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) (NCT05686408) | Tonix Pharmaceuticals, Inc. | 2023-03-02 |
| A Study to Evaluate the Efficacy and Safety of TNX-1900 in Patients With Chronic Migraine (NCT05679908) | Tonix Pharmaceuticals, Inc. | 2022-12-06 |
| Safety and Efficacy Study of TNX-102 SL in Participants With PTSD (NCT05372887) | Tonix Pharmaceuticals, Inc. | 2022-10-14 |
| A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection (NCT05472090) | Tonix Pharmaceuticals, Inc. | 2022-08-18 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL Taken Daily in Patients With Fibromyalgia (NCT05273749) | Tonix Pharmaceuticals, Inc. | 2022-04-06 |
| A Single-Dose, Randomized, Open-Label, 2-Way Crossover Study to Evaluate the Dose-Proportionality, Safety, and Tolerability of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets) in Healthy Japanese and Chinese Subjects (NCT07464535) | Tonix Pharmaceuticals, Inc. | 2022-03-18 |
| Assessment of Delayed-type Hypersensitivity Reactions to SARS-CoV-2 Peptide Antigens (NCT05216510) | Tonix Pharmaceuticals, Inc. | 2022-01-07 |
| An Open-Label, Randomized Pilot Study Comparing the Safety of a Single Dose of TNX-1300 to Usual Care (UC) Alone for the Treatment of Signs and Symptoms of Acute Cocaine Intoxication in Male Emergency Department (ED) Subjects (NCT04996056) | Tonix Pharmaceuticals, Inc. | 2021-09-03 |
| A Phase 3 Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (NCT04508621) | Tonix Pharmaceuticals, Inc. | 2020-07-22 |
| A Study To Evaluate The Efficacy And Safety Of TNX-102 SL In Patients With Fibromyalgia (NCT04172831) | Tonix Pharmaceuticals, Inc. | 2019-12-09 |
| Dose-Proportionality and Food Effect Study of TNX-102 SL (NCT04164719) | Tonix Pharmaceuticals, Inc. | 2019-10-14 |
| A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD (NCT03841773) | Tonix Pharmaceuticals, Inc. | 2019-03-07 |
| A 40-week Study to Evaluate TNX-102 SL 5.6 mg Taken Daily at Bedtime in Patients With PTSD (NCT03508700) | Tonix Pharmaceuticals, Inc. | 2018-04-19 |
| Steady-State Pharmacokinetic Comparison Study of TNX-102 SL 5.6 mg Versus AMRIX® 30 mg ER Capsules (NCT03443960) | Tonix Pharmaceuticals, Inc. | 2018-01-29 |